EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Cardiovascular sequelae of Long COVID: immune dysregulation inflammation as central drivers

Anhui Liu, Hanbing Chen, Qingxiang Liu, Mahmoud Al-Azab, Fahmi Shaher, Jiang Li, Tao Liu, Min Yang

Frontiers in Immunology · 17.06.2026 · 17

DOI: 10.3389/fimmu.2026.1815269 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Immunology, online erschienen am 17.06.2026. Verfasst von Anhui Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Wuxi School of Medicine, Jiangnan University, Wuxi, China. Hauptthemen laut MEDLINE: COVID-19, Cardiovascular Diseases, Inflammation, SARS-CoV-2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 143 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Long coronavirus disease 2019 (Long COVID-19), also referred to as post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, has emerged as a major global health challenge. Common manifestations include fatigue, dyspnea, cognitive dysfunction, and exercise intolerance. Beyond these systemic manifestations, the enduring cardiovascular manifestations are increasingly identified as core characteristics of Long COVID-19 syndromes secondary to SARS-CoV-2 infection, encompassing myocarditis, ischemic and non-ischemic heart disease, arrhythmias, heart failure, and thrombotic events. Accumulating evidence suggests that immune dysregulation and persistent inflammation are central drivers of cardiovascular injury in Long COVID. Persistent activation of innate and adaptive immune pathways fosters endothelial injury, thrombo-inflammation, and adverse myocardial remodeling. In this review, we focus on current clinical and experimental evidence to delineate the immune-mediated mechanisms underlying cardiovascular sequelae in Long COVID and explore potential therapeutic strategies targeting persistent inflammation and immune dysregulation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Cardiovascular DiseasesInflammationSARS-CoV-2HumansPost-Acute COVID-19 SyndromeImmunity, InnateAnimalsAdaptive Immunity

Stichwörter der Autor:innen

Long COVIDadaptive immune responsecardiovascular sequelaeimmune dysregulationinnate immune response

Autor:innen und Institutionen

  • Wuxi School of Medicine, Jiangnan University, Wuxi, China.
  • Department of Cardiac Vascular Surgery, Affiliated Hospital of Jiangnan University, Wuxi, China.
  • Department of Cardiac Surgery, Peking University People's Hospital, Peking University, Beijing, China.
  • School of Medicine, Southeast University, Nanjing, China.
  • Department of Emergency Medicine, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
  • School of Basic Medical Sciences, Guangzhou Women and Children's Medical Centre, Guangzhou Medical University, Guangzhou, China.

Zitieren

APA

Liu, A., Chen, H., Liu, Q., Al-Azab, M., Shaher, F., Li, J., Liu, T., & Yang, M. (2026). Cardiovascular sequelae of Long COVID: immune dysregulation inflammation as central drivers. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.1815269

Vancouver

Liu A, Chen H, Liu Q, Al-Azab M, Shaher F, Li J, et al. Cardiovascular sequelae of Long COVID: immune dysregulation inflammation as central drivers. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.1815269

BibTeX
@article{Liu2026,
  author = {Liu, Anhui and Chen, Hanbing and Liu, Qingxiang and Al-Azab, Mahmoud and Shaher, Fahmi and Li, Jiang and Liu, Tao and Yang, Min},
  title = {Cardiovascular sequelae of Long COVID: immune dysregulation inflammation as central drivers},
  journal = {Frontiers in Immunology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fimmu.2026.1815269}
}
Kostenlos starten →